Format

Send to

Choose Destination
Int J Pediatr Otorhinolaryngol. 2010 Nov;74(11):1254-7. doi: 10.1016/j.ijporl.2010.07.025. Epub 2010 Aug 30.

Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.

Author information

1
Hôpital Armand-Trousseau, 75012 Paris, France. nicolas.leboulanger@trs.aphp.fr

Abstract

OBJECTIVE:

Preliminary assessment of the efficacy of propranolol on subglottic hemangioma in children on a nation-wide scale.

METHODS:

Multicentric, retrospective study of clinical files of 14 children; pre- and post-treatment endoscopies.

RESULTS:

Mean age at diagnosis was 2.3 (0.7-4) months. Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction. Propranolol was started at 5.2 (0.7-16) months of age. This treatment was effective in all cases with a mean regression of the stenosis to 22% after 2 weeks and 12% after 4 weeks. Other medical treatments (steroids) could be stopped. In one patient, a side effect of propranolol motivated the switch to another β-blocker. In four patients, treatment was stopped after 5.2 (1-10) months with a relapse in 2 (50%) cases. One of these two patients developed a resistance to propranolol and required a surgical procedure by external approach.

CONCLUSION:

This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas. Propranolol also allows alleviation or cut-off of previous medical treatments. However, recurrences are possible after early treatment interruption.

PMID:
20800295
DOI:
10.1016/j.ijporl.2010.07.025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center